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Abstract
Background: Myeloperoxidase (MPO) is a marker of plaque vulnerability and a mechanistic bridge between inflammation
and cardiovascular disease, and thus is a suitable target for therapeutic strategy against cardiovascular disease.
Methods: Since hypercholesterolemia is associated with atherosclerosis and inflammation, we tested whether MPO
serum levels were up-regulated in Familial Hypercholesterolemia (FH) and whether acute reduction of total
cholesterol (TC) would also reduce MPO concentration. FH subjects undergoing LDL-apheresis (LDL-A) treatment
are a paradigmatic clinical model where TC rapidly plunges from extremely high to extremely low levels after
selective LDL removal, and then spontaneously rebounds to baseline conditions. This clinical setting allows
multiple intra-patient observations at different plasma TC concentrations. We measured MPO levels in serum by
ELISA tests, and in peripheral leukocytes by immunofluorescence, to learn whether they were affected by the
changes in TC levels. Serum MPO was measured before and serially up to the 14
th day following LDL-A.
Results: In both serum and peripheral leukocytes, MPO concentrations were i) higher than in sex- and age-
matched healthy controls (p < 0.01); ii) decreased with TC reduction; iii) parallel with TC time course; iv) correlated
with plasma TC. At regression analysis, plasma TC was the only variable considered that influenced MPO serum
levels (b 0.022 ± 0.010, p < 0.0001).
Conclusions: In FH the MPO serum levels were modulated through changes in the TC concentrations carried out
by LDL-A. Further study is needed to determine whether reduced MPO levels obtained by LDL-A could have any
therapeutic impact.
Keywords: Myeloperoxidase, Familial Hypercholesterolemia (FH), LDL-apheresis, plaque vulnerability, peripheral
leukocytes, total cholesterol
Background
High concentrations of myeloperoxidase (MPO) are asso-
ciated with atherosclerotic disease, marking its presence
and severity [1], and is co-localized with its pro-oxidant
products in atheroma [2,3]. Subjects with total or subtotal
MPO deficiency, a defect with a frequency of about 1 in
2000-4000 Caucasians, have lower incidence of coronary
artery disease (CAD) [4]. A functional polymorphism in
the MPO promoter gene, which leads to a twofold reduc-
tion in MPO expression, is associated with a lower risk for
angiographic evidence of CAD [5], nonfatal myocardial
infarction and cardiac death [6-8]. MPO is indicated as a
novel marker of plaque vulnerability [9,10], potentially act-
ing as a mechanistic bridge between inflammation and
cardiovascular events [11].
MPO is a member of the heme peroxidase superfamily
and is the most abundant component of primary azuro-
philic granules of leukocytes [12,13]. MPO is a major
antibacterial component that produces hypochlorous
acid (HOCl), a potent oxidant originating from chlorous
ion (Cl
-) and hydrogen peroxide (H2O2) [14,15], and is
secreted following activation of leukocytes. Leukocyte
activation and degranulation have been shown in
unstable angina [16,17], whereas leukocyte infiltrates
have been documented in coronary plaques of patients
with acute coronary syndromes [18,19]. Infiltrating * Correspondence: mpuntoni@ifc.cnr.it
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plaques.
Myeloperoxidase secreted by leukocytes degrades the
collagen layer that protects the atheroma from erosion or
abrupt rupture in the shoulder regions of coronary artery
lesions, where the shear stress of arterial blood is higher.
As a result, plaques highly infiltrated with leukocytes have
a thin fibrous cap and are vulnerable to erosion or rupture,
precipitating events to acute coronary syndromes.
While there is evidence of a direct role of MPO con-
centrations within the complex process of plaque devel-
o p m e n ta n do nt h ec h a i no fe v e n t st h a tc a u s ep l a q u e
rupture [20-22], the pathological conditions involving
MPO up-regulation are still unknown, as well as the
conditions capable of reducing MPO levels.
It is known that high cholesterol concentration trig-
gers all phases of inflammation and patients with
hypercholesterolemia show elevated markers of inflam-
mation, such as acute phase reactant proteins and adhe-
sion molecules [23,24].
Based on the above considerations, we addressed the
questions whether hypercholesterolemia is associated with
MPO up-regulation and whether MPO serum levels are
affected by cholesterol modulation. Therefore, we studied
MPO concentration in subjects with Familial Hypercholes-
terolemia (FH) undergoing LDL (Low Density Lipoprotein)
apheresis (LDL-A) treatment. This condition represents a
unique clinical model where it is possible to achieve rapid,
safe and selective marked changes in total cholesterol (TC)
plasma levels, to perform multiple measurements in the
same subject at different cholesterol concentrations and to
minimize bias interference in the relationship between cho-
lesterol and inflammation markers.
Methods
Patients
Eight subjects with heterozygous FH were studied; the
diagnosis was based on the presence of primary hyperch-
olesterolemia, tendon xanthomata, and family history of
hypercholesterolemia. All patients had history of CAD
and were free from any other organic or systemic disease
able to affect the prognosis (arterial hypertension, dia-
betes mellitus, obesity, hyperhomocysteinemia, smoking,
cancer and renal failure). All patients were on pharmaco-
logical wash-out from the previous 2 months; this period
is appropriate for management of statin-related side
effects (such as myalgia) as indicated by ACC/AHA/
NHLBI clinical advisory on the use and safety of statins
[25]. Study participants gave their written informed con-
sent and the study protocol received ethical approval.
LDL-A procedure
An extracorporeal venous-venous circulation provided a
blood flow of 90 to 120 mL/min; the initial heparin bolus
was 1500 IU followed by continuous infusion of 1000 IU/
h. Plasma was separated by a polysulfone hollow-fiber
filter (Sulflux FS-05). Two columns, each containing
150 mL of dextran sulfate cellulose, a specific sorbent of
apo B-containing lipoproteins (LiposorberLA-15), were
alternately flushed with plasma and regenerated with
0.7 mol/L saline solution followed by rinsing with Ringer’s
solution under control of an automatic adsorption-deso-
rption apparatus (MA-01; Kaneka Co, Japan). During a
3.5- to 4-hour period, a total plasma volume of 6.5 to
9.2 L was treated, corresponding to 2.5 to 3 times that of
each patient’s plasma volume [23].
Myeloperoxidase, lipid parameters, C3c and C4 comple-
ment fraction, haptoglobin, a1-antitrypsin, a2-macroglo-
bulin, a1-acid glycoprotein, ceruloplasmin and routine
laboratory tests, including complete blood count, were
measured before LDL-A treatment and serially up to the
14
th day following each treatment. Each patient was conse-
cutively studied three times.
First samples after LDL-A were taken immediately
before saline infusion to wash out the extracorporeal cir-
culation components, in order to avoid any hemodilution
effect.
Finally, to assess possible absorption by the extracorpor-
eal circuit components, MPO levels were measured in sam-
ples simultaneously taken from the inlets and the outlets of
the plasma separator and the dextran sulfate column, both
at the beginning and at the end of the LDL-A procedure.
Pre-treatment values were compared with those mea-
sured in eight healthy control subjects matched for age
and sex.
Laboratory Analysis
Total cholesterol (TC), triglycerides (TG) and HDL (High
Density Lipoprotein) cholesterol (HDL-C) were measured
in duplicate by standard enzymatic techniques (Synchron
CX9 Pro, Beckman Coulter, Inc. Fullerton, CA, USA);
LDL cholesterol (LDL-C) was calculated according to Frie-
dewald et al. [26]. Hematocrit, complete blood count and
differential were determined in K3EDTA-anticoagulated
blood samples using an automated Coulter counter
(model MAXM, Instrumentation Laboratory, Miami, FL,
USA), with a sample size of up to 8000 cells. Acute phase
reactant proteins (APRs) were assayed by rate nephelome-
try (BN- ProSpec, Siemens Healthcare Diagnostics, Italy).
Routine chemical clinical analyses were performed by
standard methods with strict quality control. MPO
serum levels were measured by commercial ELISA assay
(OxisResearch, OR, USA). All measurements were
assayed in one batch on serum stored at -80°C.
PMN isolation and immunofluorescence
Polymorphonuclear (PMN) cells were isolated from FH
and healthy control peripheral blood by Ficoll/Hypaque
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dextran sedimentation and erythrocytes hypotonic lysis
[27]. PMN-rich supernatant was used for immunofluor-
enscence analysis [28] using a first primary human anti-
body anti-MPO and a secondary antibody IgG
conjugated to FITC (Santa Cruz).
Visual evaluation of immunofluorescence was per-
formed by coupling the microscope AxioSkop 40 (Zeiss,
Germany) to a digital camera AxioCam MRm (Zeiss). A
FITC filter was used for the fluorescence wave-length.
Standard optical magnifications (20× and 100×) were
used with a fixed exposure setting (color digital images
were stored in JPEG format for off-line analysis).
To quantitatively evaluate the fluorescence intensity in
the cells, the acquired images were processed by the
public domain Image Java application (National Institute
of Health, Bethesda, MD, USA).
Since the pictorial information is virtually monochro-
matic, the intensity map of the image was studied accord-
ing to an 8-bit dynamic (256 gray levels, 0 = black, 255 =
white). The background luminescence intensity was mea-
sured inside the nucleus and subtracted. By means of
threshold operations, the intracellular area (excluding the
nucleus) was acknowledged and measured.
Examples of the histograms obtained are shown in
Figure 1. In order to describe and compare the grey level
histograms, the mean and the standard deviation, related
to the global brightness of the cell and to the overall con-
trast respectively, were measured in each image (see
Appendix).
Statistical Analysis
Data were expressed as mean ± Standard Error (SE).
Variables showing no normal distribution, checked by
Chi-squared test, were logarithmically transformed when
appropriate. The parametric paired t-test was used to
investigate the differences in mean of lipid profile, APRs
and MPO between FH patients and controls.
The partial Pearson Correlation coefficient was used
to test the correlation between MPO, variable of lipid
panel and APRs, removing the effects of the other con-
founding variables studied.
The Random Effects Linear Regression Model for
repeated measures [29] was used to assess the effect of
time on TC, time on MPO, TC on MPO; for each regres-
sion analysis, b-regression coefficient ±2 SE and p-value
was reported. The locally weighted scatterplot smoothing
(LOWESS) technique [30] was used to further analyze the
bivariate relationships between MPO and independent
variables; this technique is designed to produce a smooth
fit to the data and reduces the influence of extreme out-
liers. All analyses were performed by the statistical package
Stata 8 SE [31].
Results
Pre-treatment lipid profile, APRs and MPO concentrations
of FH patients and healthy controls are shown in Table 1.
As expected, compared to controls, patients’ lipid profiles
were characterized by higher TC and LDL-C (p <0 . 0 0 1 ) ;
also, APR values were higher in FH than in controls;
patients’ MPO concentrations resulted in a tenfold
increase relative to controls. This latter condition was evi-
dent at the cellular level too: as shown in Figure 1,
patients’ PMN showed more intense azurophilic granules
compared to those isolated from healthy controls.
Effect of LDL apheresis treatment
LDL apheresis treatment dramatically reduced lipid con-
centration: TC decreased from 343.1 ± 14.7 to 62.5 ±
9.2 mg/dl (-83%), LDL-C from 253.1 ± 16.9 to 28.9 ±
3.0 mg/dl (-90%) and TG from 196.1 ± 61.1 to 28.6 ±
5.6 mg/dl (-86%).
Within 14 days all lipoproteins rebounded to pre-
treatment values; TG regressed to baseline values within
48 h. The TC time-course is shown in Figure 2; the cal-
culated TC increase was 20.69 ± 1.46 mg/dl per day
(b regression coefficient 20.69 ± 2.92, p < 0.001).
Routine laboratory tests, including complete blood
count, resulted in normal range and did not change
throughout the study. After LDL-A, MPO levels
decreased from 20.4 ± 3.3 ng/dl to 12.9 ± 5.0 ng/ml
(-36.3%, p < 0.0001), thereafter MPO increase was 0.48
± 0.15 ng/dl per day (b regression coefficient 0.48 ±
0.30, p < 0.005). MPO time-course is shown in Figure 3.
Rebound curves of TC and MPO had a similar pattern
(Figures 2 and 3).
The partial correlation between MPO, TC (LDL-C,
TG and HDL-C were excluded by analysis due to the
degree of high correlation with TC), APR variables and
adhesion molecules, show that only TC had a significant
effect on MPO levels (Table 2).
As a consequence, we performed a linear regression
analysis between MPO and total cholesterol levels,
showing a 0.022 ng/ml MPO increase for each 1 mg/dl
TC increase (b regression coefficient 0.022 ± 0.010, p <
0.0001; Figure 4).
APRs and lipid factors were reduced after LDL-A
treatment and showed a positive correlation with choles-
terol values, as previously described [23,32] throughout
the study (data not shown).
No difference was found between inlet and outlet
MPO values.
Discussion
In this study we found that: 1) MPO serum levels are up-
regulated in patients with FH compared with controls;
2) decreased TC concentration with LDL apheresis is
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concentration is the main determinant of MPO serum
levels between the variables considered.
All these data suggest that high TC levels could be a
pathological condition leading to MPO up-regulation, by
mechanisms that remain to be elucidated.
Figure 1 MPO Immunofluorescence of PMN cells from FH patient and healthy control. Panel A. Fluorescence Microscope preparation of
PMN cells from FH patient (left) and healthy control (right). Secondary FITC conjugated antibody was used against human anti- MPO antibody.
Panel B. Distribution of the pixel luminous intensity, described as histogram of the frequency of the brightness amplitude levels.
Table 1 Lipid, acute phase reactans and myeloperoxidase concentrations in FH patients and controls
FH (n = 8) Controls (n = 8) *p -value
Total Cholesterol (mg/dl) 343.1 ± 41.6 214.5 ± 32.0 < 0.001
Triglycerides (mg/dl) 196.1 ± 172.7 82.5 ± 41.4 ns
High Density Lipoprotein (mg/dl) 50.9 ± 12.0 53.6 ± 10.5 ns
Low Density Lipoprotein (mg/dl) 253.0 ± 47.7 144.4 ± 23.9 < 0.001
C Reactive Protein (mg/dl) 0.12 ± 0.08 0.08 ± 0.06 ns
C3c complement fraction (mg/dl) 135.6 ± 22.1 92.6 ± 11.3 < 0.001
C4 complement fraction (mg/dl) 31.4 ± 15.7 19.6 ± 5.5 ns
Haptoglobin (mg/dl) 114.6 ± 58.8 62.6 ± 26.5 < 0.05
a1-Antitrypsin (mg/dl) 151.7 ± 27.0 89.4 ± 12.3 < 0.001
a2-Macroglobulin (mg/dl) 183. ± 68.9 130.2 ± 31.5 < 0.05
a1-acid Glycoprotein (mg/dl) 81.5 ± 12.7 50.9 ± 4.7 < 0.0001
Ceruloplasmin (mg/dl) 24.2 ± 3.1 23.5 ± 6.7 ns
Myeloperoxidase (ng/dl) 20.4 ± 3.3 1.9 ± 1.5 < 0.01
Values are mean ± SE, *parametric paired t-test.
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supports the hypothesis that hypercholesterolemia is a
strong pro-inflammatory condition. Data mainly refer to
the relationship between high TC and the sub-acute and
long-lasting inflammation markers.
MPO is a marker of an acute inflammatory response.
It is the main component of the first host defense and
rapidly responds to stimuli. MPO secretion leads to spe-
cific inflammatory pathways considered to be links with
clinical manifestation of acute coronary syndromes
Figure 2 Relationship between total cholesterol and time. Locally weighted scatterplot smoothing (LOWESS) technique was used to fit the
relationship between TC and time (p and b regression correlation).
Figure 3 Relationship between myeloperoxidase and time. Locally weighted scatterplot smoothing (LOWESS) technique was used to fit the
relationships between MPO and time (p and b regression correlation).
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of the atheroma fibrous cap and its increased vulnerabil-
ity to erosion or rupture).
The MPO reduction obtained upon LDL-A would
strengthen the relation between TC and MPO concentra-
tion. The measured MPO reduction could be underesti-
mated because heparin used during the extracorporeal
circulation detached the MPO stuck on the artery wall, a
well-known phenomenon [33] though not measured here.
MPO serum levels do not return to the pre-treatment
concentrations for up to 7 days, but rebound after LDL-
A in a manner similar to cholesterol, further suggesting
a close relationship between the two variables.
From the statistical analyses we excluded the values
measured soon after the treatment in order to avoid bias
due to: i) ap o s s i b l en o n - s p e c i f i cM P Or e d u c t i o nv i a
binding to dextran columns (although we found no
changes in MPO values from inlet and outlet dextran col-
umns) and ii) the effects of leukocytes activation (as in
other systems, such as the complement system) that
occur during the interaction with extracorporeal circuits.
Regarding last point, it is important to recall that the leu-
kocyte half-life is about 6 hours; upon their activation the
MPO increases and not vice versa. The circulating leuko-
cytes live 2 days after LDL-A, so they have no treatment
memory, including their synthesis and secretion.
The significant association between MPO and TC
shown here may not depend on the peculiarities of the
clinical model used but instead assume a general biologi-
cal and clinical meaning. This consideration is supported
by the wide range of plasma total cholesterol explored
(from 60 to over 400 mg/dl) and by the linear MPO
increase of 0.022 units for each 1 mg/dl TC increase.
Changes seen (data not shown) in APRs listed in
Table 1 are consistent with the interpretation of MPO
Table 2 Partial MPO correlation with total cholesterol,
acute phase reactans and adhesion molecules in FH
patients
b p-value
Total cholesterol 0.3288 < 0.01
C-Reactive protein 0.0247 ns
C3c complement fraction 0.0025 ns
C4 complement fraction 0.0748 ns
Haptoglobin 0.1522 ns
a1-Antitrypsin 0.0546 ns
a2-Macroglobulin 0.1642 ns
a1-acid glycoprotein 0.1808 ns
Ceruloplasmin 0.0133 ns
sICAM 0.1884 ns
sELAM 0.1968 ns
sVCAM 0.1183 ns
Figure 4 Simple linear regression between MPO and TC. Random Effects Linear Regression Model for repeated measure (p and b regression
correlation).
Puntoni et al. Lipids in Health and Disease 2011, 10:185
http://www.lipidworld.com/content/10/1/185
Page 6 of 8being a principal actor in an acute and rapid inflamma-
tory response (mediated by leukocytes). This is an
important phenomenon within the intriguing process of
arterial wall vulnerability, and it is part of a larger
inflammatory response that occurs in the high-choles-
terol state. In our patients CRP levels were higher,
though not significantly, compared to controls, although
lower than those of untreated hypercholesterolemic
patients. This apparent contradiction may be explained
by the long-lasting effect of LDL-A on chronically trea-
ted FH patients, which could have attenuated the
inflammation [32].
The main study limitation is the lack of a causal rela-
tionship between MPO concentration and cholesterol
levels, instead of simply a description of the phenom-
enon. Furthermore, the leucocyte MPO data provided
by immunofluorescence are only qualitative.
The relationship between TC and MPO as an index of
leukocyte activation offers interesting biological possibi-
lities, but surely more studies will be needed to elucidate
the underling mechanisms.
Conclusions
This study identifies a significant association between
total plasma cholesterol levels and MPO in patients
affected by Familial Hypercholesterolemia and suggests
the possibility of modulating MPO plasma concentration
by cholesterol levels.
Study limitations
The small number of patients chronically treated with
LDL apheresis is a limitation of the present study and has
to be acknowledged. There are few FH patients with clini-
cal indication to LDL-A and only some of these patients
had the pathophysiologic conditions to interrupt their
pharmacological treatment for two months that is an
appropriate period for management of statin-related side
effects (like specified in Methods regard patients).
Appendix
Imaging processing using the most recent tools and digi-
tal techniques aims to describe, by means of statistical
approaches, the overall feature of the pictorial scene in
terms of “tone”, a concept related to the shades of grey of
the elementary pictorial elements (pixels) of the digital
representation. First order statistics is a lower-level
approach, providing a wide variety of parameters for the
quantitative description of the shape of the histogram of
the grey level amplitude (tonal) distribution of the
selected regions of interest. The simplest descriptors of
the overall feature are given by typical parameters
extracted from the grey level distribution (without con-
sidering spatial interdependencies). In particular, by con-
sidering the digital image as a matrix of equally sized
pictorial elements (pixels), and by calling (gij)t h eg r e y
level of the pixel of co-ordinates (i, j) inside the matrix of
the region of interest R, and N the total number of grey
values, the following features are defined:
- the mean (m), which describes the average grey
value of the distribution; it is related to the overall light-
ness/darkness of the pictorial data; in the specific case,
it quantifies the average amplitude of immunofluores-
cence in the image.
- standard deviation, that is the expression of spreading
of distribution from the mean, i.e. the overall contrast.
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